35 results about "Early Cancer Detection" patented technology

MK (midkine) was found to rise in the blood or urine of patients with various types of cancers at early stage. Based on this finding, a method for detecting early cancer, comprising the step of measuring MK in blood or urine was completed.

The invention belongs to the technical field of medical image intelligent processing, in particular to a gastrointestinal endoscopic image classification and early cancer detection system based on a multi-task neural network. The system of the invention comprises: (1) a feature extraction backbone network; (2) Classification of gastrointestinal endoscopic images; (3) regional detection branch of early gastrointestinal cancer. The invention adopts a multi-task depth neural network structure, and classifies and detects two tasks to share a plurality of convolution layers. Endoscopic images are inputted into the neural network model, and the detection and classification results can be obtained simultaneously after a forward propagation, which can effectively reduce the computational load andimprove the classification and detection accuracy. The experimental results show that the invention can accurately classify the endoscopic images into normal and early cancers and detect the irregularlesion areas in the early cancers images, reduce the influence of human factors and improve the efficiency of clinical diagnosis.

The present invention provides methods of detection, including early detection, for cancer or other diseases and normal physiologic processes mediated by global epigenetic changes, by using one or more of the following biomarkers: a global DNA methylation index, a global histone H4 acetylation index, and a global histone H4 trimethylation index. These methods are useful for, among other things, assessing the effectiveness of treatment, monitoring relapse, and clinical staging of cancer and other chronic as well as acute diseases. These methods are also useful for among other things monitoring the effectiveness of strategies and therapies used to modify lifestyle and contextual effects to prevent disease, foster wellness and enable health promotion.

Luminescent semiconductor quantum dots (QDs) conjugated with biomolecules to serve as sensitive probes for early detection of the cancer cells, specifically for ovarian cancer and lung cancer, which represents the most lethal malignancies. The luminescence characterization of the bin-conjugated QDs with cancer specific antigens using linkage molecules. Photo-enhancement is measured at various laser density power, temperatures and laser wavelengths.

The present invention relates to a diagnostic unit for diagnosing early cancel depending on fluorescent image. The invention adopts a real time display method for fluorescent image, which has high spatial-resolution and high time-resolution for the purpose of collecting information about all fluorescent images of diagnostic area at any time without omission of any detail. Method of the present invention is prior to method catching static images in diagnosis, and the invention prevents mistakes and missed check caused by failure in acquiring static images timely and accurately in order to improve accuracy rate during the test of early cancer. The present invention has the advantages of accurate, direct, convenient and easy operation with no side effects, which can be used in diagnosing all malignant tumors inside and outside human body. Before operation, the present invention can favor fixing range of the operation. When in operation, the invention can conduct tracking and check so as to adjust effect of the operation and suggest for removing residual tumor in time.

The present invention relates to a fully quantitative spectroscopy imaging instrument for wide area detection of early cancer (dysplasia). This instrument provides quantitative maps of tissue biochemistry and morphology, making it a powerful surveillance tool for objective early cancer detection. The design, construction, calibration, and diagnostics applications of this system is described with the use of physical tissue models. Measurements were conducted on a resected colon adenoma, and the system can be used for vivo imaging in the oral cavity.

Methods using the application of the Ca isotope method for diagnosing and monitoring the progression of cancers that cause bone loss. The methods also can be used for evaluating cancer treatments, such as aromatase inhibitors and other chemotherapeutic agents, for effects on bone density so that treatment can be modified.

This invention discloses a realization method and a device for automatically amplification of a lens of an early-stage cancer detector. The device comprises a camera, a microscope with a amplification times adjustment ring, and a amplification times adjustment mechanism controlled by a central control system. The central control system obtains the current amplification times of the microscope, compares the current amplification times with a preset amplification times and controls the amplification times adjustment mechanism according to the comparison result. The amplification times adjustment mechanism controls the amplification times adjustment ring of the microscope to rotate to a preset position. Through comparing the current amplification times with the preset amplification times and controlling the amplification times adjustment ring to rotate so as to realize the automatic adjustment for the amplification times of the lens.

The invention relates to a design method and application of a probe combination for cancer detection. The design method comprises the following steps: extracting a mutation set of cancer in a database, dividing the mutation set into a training set and a verification set, and combining mutations with reference genome distance less than or equal to 80 in the training set so as to obtain a plurality of mutational hotspot intervals; and sequentially screening the multiple mutation hotspot intervals on the basis of the regional mutation density, and taking the mutation hotspot intervals meeting the following conditions as targets of the probe combination. The probe combination designed by the invention has excellent coverage on common cancers, a Gene+ database and MSK database verification set is adopted to simulate the coverage condition of the panel on nine cancers, and the result shows that the coverage degrees of nine cancer types are all greater than 93%; the early cancer detection based on the probe has high sensitivity and specificity, and the detection rate of liver cancer reaches 85%; and a ctDNA positive judgment method based on the probe can effectively perform prognosis layering on a patient.

The present invention discloses a highly efficient method of isolating circulating tumor cells in a blood sample by removing leukocytes and other interfering components in a blood sample. Exemplary isolation method relies on a specially configured separation column for magnetic separation of leukocytes from circulating tumor cells. Also disclosed are systems, devices, and reagents for performing the method, as well as diagnostic methods for early cancer detection, screening, and treatment monitoring utilizing the cell isolation method.

The invention discloses an early-stage cancer detection method based on a terahertz attenuated total reflection mode, a physical model of interaction between multiple interfaces of a total reflectionsurface, a sample pool bottom surface, a cell layer and a buffer solution layer and evanescent waves is established, and total reflection occurs at the sample pool bottom surface-cell layer interfacebecause the total reflection surface and the sample pool bottom surface are made of the same material. The detection of the terahertz characteristic fingerprint spectrum based on the cells has highersensitivity and accuracy than the detection based on the cell morphology.

The invention provides a mesothelin antibodynano test paper and carbon nano tube combined cancer detection method, and solves the problems existing when a carbon nano tube is adopted to replace the traditional early cancer detection method. The combined cancer detection method is characterized in that combination of a mesothelin antibody and a carbon nano tube material is adopted, a mixed liquid composite material of a virus antibody and the carbon nano tube is used as a new virus detection tool, after the mesothelin antibody on the surface of the carbon nano tube acts with mesothelin in the blood of a tested person, the mesothelin is attached to the carbon nano tube and combined with the mesothelin antibody to expand the antibody, and the interaction between the antibody and antigen results in change of electrical conductivity of the carbon nano tube, so that the content of the mesothelin in the tested person is determined. The mesothelin antibody nano test paper and carbon nano tube combined cancer detection method has the advantages that the detection sensitivity and selectivity are good, false positive and false negative are absent, samples of a general patient and a patient suffered from pancreatitis can be ignored, and the efficiency is about 100 times of the efficiency of the conventional diagnostic test, and the method is suitable for early detection of cancers such as cholangiocarcinoma, stomach cancer, pancreatic cancer, ovarian serous carcinoma and the like.

BF819 is a biomarker for the early detection of cancer. The natural polypeptide sequence of BF819 is disclosed along with the sequence of an epitope bound by a novel mAb BF819 used in tests and methods for cancer detection. Specific cancer and tumor types are identified where BF819 is overexpressed along with data showing the extent of the detection of BF819 in cancer, normal, and benign conditions.

Disclosed are a method and a system for monitoring early cancer risk. Most current early cancer detection and diagnosis are related with gene and biomarkers, although the practice has proven the significant differences of blood and urine test results between cancer patients and healthy people, and obtaining the results of routine blood and urine tests is not difficult, the use of routine blood and urine tests to detect and monitor early cancer risk has never been reported; and traditionally, early cancer detection and monitoring have been managed by doctors and hospitals, the users are unable to do it themselves. The purpose of this invention is to provide an early cancer risk monitoring system enabling users to dynamic monitor the early cancer risk.

The invention relates to a sensing array capable of distinguishing cells. The sensing array provided by the invention comprises five tetraphenyl ethylene derivatives with mitochondrial targeting and aggregation-induced emission effects. According to the tetraphenyl ethylene derivatives disclosed by the invention, a molecular probe D-A structure is adjusted by adjusting donor-acceptor groups and different cationic groups, so that different fluorescence spectrum properties are realized, and different electrostatic and hydrophobic interactions with cells are realized; the synthesis is easy; goodbiocompatibility and light stability are realized; cell mitochondria can be effectively targeted for cell imaging; different probes and different cells generate differential fluorescence response; byanalyzing different fluorescence responses, different cancer cells can be discriminated and cell types can be predicted. A new method for early cancer detection is designed and has potential application in the aspect of cancer cell clinical examination.

This invention discloses a realization method and a device for automatic focusing of an early-stage cancer detection device. The steps of fine adjustment comprises: acquiring images of preset identifiers, wherein the preset identifier consist of a plurality of black stripes and a plurality of white stripes, and the preset identifier possesses a black gray value standard interval A and a white gray value standard interval B; b) acquiring the real gray values of all black stripes and the real gray values b of all white stripes; c) determining whether a and b respectively fall into the black gray value standard interval A and the white gray value standard interval B; and d) circulating until the a and the b respectively fall into the black gray value standard interval A and the white gray value standard interval B. Through the gray value comparison, the lens and the height of the lense can be adjusted automatically, which avoids manual operation and has high uniformity and adjustment accuracy.

The invention relates to the field of cancer detection, in particular to a method for building an optimal hyperplane. The method comprises the following steps of selecting a plurality of normal person and cancer patients as samples, and obtaining protein information of all the samples; utilizing the protein information to establish a protein information feature data space of all the samples; according to Tanimoto distance, building the optimal hyperplane, wherein the optimal hyperplane is used as a classifier for identifying the normal persons and the cancer patients. The invention also provides a dynamic correction system for early cancer detection. The method has the advantages that the optimal hyperplane is built according to the protein information of the samples, and is used as the classifier to identify the normal persons and the cancer patients; the protein information and the protein information feature data space are classified, and the Minkowski distance metric and slack variable are introduced into the protein information feature data space, so as to improve the building of the optimal hyperplane; finally, the combined component classifier is dynamically designed, so as to realize the intelligence and accuracy optimizing of the system.

The present invention provides a quantitative liquid biopsy diagnostic system and methods for performing diagnostic assays. The system offers a liquid biopsy method using circulating tumor cells (CTCs) or White Blood Cells (WBC) subpopulations for precision cancer diagnosis, early detection of disease evolution, and cancer patient management. The invention utilizes selective plane illumination microscopy (SPIM) to deliver high sensitivity and specificity for the detection and isolation of individual CTCs, superseding the efficacy of existing methodologies for early cancer detection. Isolated CTCs can be analyzed for their molecular fingerprint, which can lead to matching genetic abnormalities with specific drug treatments. The system allows ex vivo observation of live CTC or WBC response to treatment. This observation of live cells offers the oncologist a new potential for optimizing therapeutic protocols by testing a patient's own cells, and then administering treatment to the patientwith the expectation of improving efficacy and reducing toxicity to normal cells.

The invention discloses a cell level nondestructive fluorescence detection spectrograph. The cell level nondestructive fluorescence detection spectrograph comprises an exciting light source; an exciting light probe is connected to the lower end of the exciting light source; the exciting light probe is connected with an exciting light position control system through an exciting light probe fixing device; a precision NC motor is arranged on the exciting light position control system; a sample cell for placing cell samples is formed under the exciting light probe; and a fluorescence spectrum collecting and analyzing system is under the sample cell. The sample cell is formed a sample cell position control system which is hollowed-out in the middle and fixed on the surrounding. The cell level nondestructive fluorescence detection spectrograph disclosed by the invention can be used for single cell / sub-cell fluorescence analysis, can realize phosphorescence life testing and can detect the change of fluorescence intensity with time within a time scale range from milliseconds to hours; and the cell level nondestructive fluorescence detection spectrograph disclosed by the invention can be used for single cell / sub-cell fluorescence microscopy imaging, micro-area fluorescence spectrum analysis and integral steady-state fluorescence spectrum analysis in the X-Y direction and has greater guiding significance in early cancer detection and screening.

The invention discloses a C-shaped infrared mammary gland detector. From top to bottom, the C-shaped infrared mammary gland detector comprises a camera platform, a supporting platform, an adjusting device, a power control device and a travel device, wherein the supporting platform comprises a horizontal supporting piece and a vertical supporting piece; the power control device is a power switch; the travel device includes rolling wheels; and the camera platform comprises a C-shaped projecting camera and a display which are mutually connected. The mammary gland detector provided by the invention is convenient to operate and uniform in illumination, accurate in data and labor-saving, and mammary gland images under an infrared light source can be conveniently collected. Both the C-shaped projecting camera and the display have function of increasing and decreasing light sources, zooming in and zooming out images, picking up images and freezing images, and the C-shaped projecting camera and the display are convenient to control. The mammary gland images can be directly projected on breasts, or the mammary gland images are transmitted to the display or the mammary gland images are transmitted to external equipment; with the application of the three ways, the mammary gland tissue images can be observed; and the C-shaped infrared mammary gland detector is convenient for observation and is high in early cancer detection accuracy rate.

The invention includes a method for detecting benign to malignant transformation of cancer in a subject comprising the steps of: collecting a sample from the subject prior to electrophoretic protein separation; activating electrophoretic separation of ENOX2 transcription using an ENOX2 electron donor and detecting the presence of one or more activated ENOX2 transcript variants using a pan-ENOX2 detectable binding reagent, wherein the presence of the one or more activated ENOX2 transcript variants in the sample indicates malignant transformation of the cancer, Thereby a 10 to 100-fold increase in the detection sensitivity of one or more activated ENOX2 transcript variants is obtained when compared to an equivalent non-activated ENOX2 transcript variant.

The invention relates to the field of cancer detection, in particular to a method for building an optimal hyperplane. The method comprises the following steps of selecting a plurality of normal person and cancer patients as samples, and obtaining protein information of all the samples; utilizing the protein information to establish a protein information feature data space of all the samples; according to Tanimoto distance, building the optimal hyperplane, wherein the optimal hyperplane is used as a classifier for identifying the normal persons and the cancer patients. The invention also provides a dynamic correction system for early cancer detection. The method has the advantages that the optimal hyperplane is built according to the protein information of the samples, and is used as the classifier to identify the normal persons and the cancer patients; the protein information and the protein information feature data space are classified, and the Minkowski distance metric and slack variable are introduced into the protein information feature data space, so as to improve the building of the optimal hyperplane; finally, the combined component classifier is dynamically designed, so as to realize the intelligence and accuracy optimizing of the system.

The invention relates to a DNA nano-origami structure constructed by DNA rolling circle amplification technology and DNA origami. At the same time, the fluorescent dye DAPI with DNA double-strand binding characteristics and cell membrane penetration characteristics is used to mark and track the DNA nano-origami structure. Real-time monitoring and simulating the drug loading and sustained release process of DNA nano-origami structure as a drug carrier can also be used as a new fluorescence quantitative analysis method for biomolecular detection, such as early detection of tumors, postoperative monitoring and evaluation, and cell imaging, etc. field.

The present invention is a fluorescence image early cancer diagnostic instrument. The present invention adopts a dynamic and real-time display method of fluorescence images, which not only has extremely high spatial resolution, but also has extremely high time resolution, and can collect all the fluorescence image information of the diagnosis area at any time. , without missing any detail. It is much superior to the method of capturing still images for diagnosis, and it also greatly avoids errors and missed detections caused by not capturing still images in time and accurately, thereby greatly improving the accuracy of early cancer detection. The invention has the advantages of accuracy, intuition, no side effect, simple operation method and the like, and can be used for diagnosing various malignant tumors in vivo and in vitro. Moreover, it can help determine the scope of the operation before the operation, and can also be followed up during the operation to judge the effect of the operation and provide instructions for timely removal of residual tumors.

The invention belongs to the technical field of biomedical engineering, and relates to an integration imaging system used for early stage cervical carcinoma detection and integrating fluorescent mesoscope imaging and optical coherence tomography (OCT). The integration imaging system comprises a fluorescent mesoscope imaging system and a spectrum OCT system. The fluorescent mesoscope imaging system comprises a laser light source, a polarizer, a polarized light spectroscope, a first dichroscope, a second dichroscope, an X-Y scanning galvanometer, an objective lens, a fluorescent detection part, a diffused light detection part and a computer, wherein the X-Y scanning galvanometer and the objective lens are shared by the spectrum OCT system. The spectrum OCT system comprises a low-coherent light source, a fiber polarization splitter, a focusing lens, the X-Y scanning galvanometer, the objective lens and a spectrograph. Ultraviolet light beams generated by the laser light source pass through the polarizer, the polarized light spectroscope and the first dichroscope and then are reflected through the second dichroscope, and samples generated by the low-coherent light source are collimated through the focusing lens and are combined with the ultraviolet light beams. The system improves diagnostic specificity through mutual evidence of organization function information and histomorphology information.

The invention belongs to the technical field of cell capture devices and relates to a novel microfluidic array for efficient cell capture. A monomer of the microfluidic array is arched microcolumns defined by sections of arcs and corresponding chords, and the height is 30-50 microns. The chords of the arched microcolumns are parallel to a fluid in direction and correspond to the arcs adjacent to the microcolumns in a one-to-one way. The central lines of the adjacent two columns of arched microcolumns are parallel and are distributed in a staggered way, and the central straight lines of the adjacent two columns of arched microcolumns are parallel. The microfluidic array is simple in structure and convenient to manufacture and process, can be applied to clinical test of microfluidic chips later, improves the tumor cell capture rate and detection sensibility and is conductive to early cancer detection and finding.

The invention relates to an inspection system for improving the accuracy of a tumor marker, which comprises a sample, an ultrasonic signal generation assembly and an electrode, the ultrasonic signal generation assembly acts on the sample through an ultrasonic probe, and the electrode captures the tumor marker in the sample through a capture probe. The capture probe and the electrode are used for enriching and amplifying signals, transmitting the signals to the electrochemical workstation and converting the signals into electrochemical signals; according to the detection system provided by the invention, a serum tumor marker signal of a detection sample is amplified through an ultrasonic signal, the relative signal intensity of an early tumor marker is enhanced, the sample to be detected is captured by a capture probe, the signal is enriched and amplified through a supramolecular material, an electroactive material, a nano material and the like, the signal is converted into an electrochemical signal, and the linear relationship between the electric signal and the concentration of the to-be-detected standard substance is determined, so that the quantitative detection of the to-be-detected sample is finally realized, and the sensitivity and specificity of early cancer detection can be effectively improved.

The present invention relates to an in situ hybridization detection kit for early cancer. The kit includes a hybridization probe, a label and a synergist, wherein the sequence of the hybridization probe is shown in SEQ ID NO:1. The present invention also provides an in situ hybridization detection method of HMG-1 gene, the method comprising the following steps: a. contacting the hybridization probe in the kit with the RNA to be detected in the substrate to form a hybridization complex; b. Detect the hybrid complex obtained in step a. The present invention also provides the application of the kit in the preparation of drugs for detecting early cancer diseases. The invention has the advantages that: the kit provided by the invention has the characteristics of high sensitivity and strong specificity; the detection method of the invention is convenient and simple to operate, and can be widely used and popularized in hospitals above the district level.

The invention discloses an early cancer detection method based on a single cell level. According to the method, lactic dehydrogenase is modified on the tip of a nano-probe, a human breast cancer cellline MCF7 is selected as a cell strain for testing, and the concentration of the extracellular lactic acid of tumor cells can be monitored by catalyzing the conversion of the lactic acid and generating NADH as a fluorescent detection object. The detection method is accurate in detection result of the concentration of the extracellular lactic acid of the cells and is capable of truly reflecting a single cell fluorescence signal value corresponding to a certain concentration, so that the extracellular release of the lactic acid can be reflected truly and accurately. According to the detection method, the metabolism of normal cells and cancer cells can be distinguished from the single cell level, and the method has important significance for understanding a molecular mechanism of cancerationand diagnosis and prognosis of early cancers.

The invention is applicable to the technical field of biomedical detection, and provides a label-free tumor marker detection system based on a micro-nano structure optical chip and a preparation method of the micro-nano structure optical chip, the detection system comprises a hardware detection system, a background service system and a remote terminal system; the hardware detection system is used for detecting trough data of reflection valleys on the surface of the micro-nano structure chip and calculating offset data of the reflection valleys on the surface of the micro-nano structure chip according to the trough data; the background server comprises a cloud server for transmitting offset data, a database for storing the offset data and an internet platform for distributing data to users; and the remote terminal system is used for presenting the visual detection result to a user. The label-free tumor marker detection system based on the micro-nano structure optical chip is low in cost and better in portability, and early cancer detection is more accurate, intelligent and rapid.